polivy-logo-triangle.svg

A clinical benefit full of life

POLIVY-R-CHP: the first clinically meaningful improvement over a standard of care that held for 20 years1-13

Watch Expert Perspectives

Specialist views covering a range of POLARIX trial topics

watch-expert-perspectives-image1.png

Dr Hervé Tilly,
University of Rouen, France

watch-expert-perspectives-image2.png

Prof. Christopher Flowers,
MD, Anderson Cancer Center, University of Texas

watch-expert-perspectives-image3.png

Dr Franck Morschhauser,
MD, PhD Professor of Hematology,
University of Lille

watch-expert-perspectives-image4.png

Dr Laurie H. Sehn,
MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

27-percent-min.png

reduced risk of progression, relapse, or death with

POLIVY-R-CHP vs R-CHOP.1,*

That means more hope for the future, and more freedom from the threat of disease.

POLARIX Trial

What is the POLARIX trial?

A phase III trial to compare the
efficacy and safety of polatuzumab
vedotin in combination with R-CHP
vs R-CHOP in 1L DLBCL1

Efficacy

Was a meaningful benefit seen for 1L DLBCL patients?

The POLIVY-R-CHP regimen
demonstrated a clinically
meaningful progression-free
survival benefit over R-CHOP1

Safety

Were there any safety concerns?

The overall safety profile of
POLIVY-R-CHP is similar to that of R-CHOP and consistent with the known risk of the individual study drugs1

quote-icon.png

“The new regimen should reduce the risk of relapse and help patients avoid intensive treatments such as stem cell transplantation and chimeric antigen receptor T-cell therapy.”14

– Dr Gilles Salles, MD, PhD

Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center

Group9906@2x.png

About POLIVY

Considering using 
POLIVY-R-CHP for your patients?

Learn more about dosage, administration, and mechanism of action

*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; P=0.021
1L=first line; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Aurer I, et al. Eur J Haematol. 2011;86:111-6.
  3. Bartlett NL, et al. J Clin Oncol. 2019;37:1790-9.
  4. Coiffier B, et al. N Engl J Med. 2002;346:235-42.
  5. Cunningham D, et al. Lancet. 2013;381:1817-26.
  6. Davies A, et al. Lancet Oncol. 2019;20:649-62.
  7. Iacoboni G, et al. Ann Oncol. 2018;29:1120-9.
  8. Jaeger U, et al. Haematologica. 2015;100:955-63.
  9. Seymour JF, et al. Haematologica. 2014;99:1343-9.
  10. Vitolo U, et al. J Clin Oncol. 2017;35:3529-37.
  11. Vitolo U, et al. Hematol Oncol. 2019;37:36-7.
  12. Witzig TE, et al. Ann Oncol. 2018;29:707-14.
  13. Younes A, et al. J Clin Oncol. 2019;37:1285-95.
  14. ASCO Post. 2021 [cited 2022 15 July]. Available from: https://ascopost.com/news/december-2021/polarix-pola-r-chp-vs-r-chop-for-previously-untreated-patients-with-dlbcl/.